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For over two decades now, the recombinant form of
erythropoietin (RhEPO) is used for the treatment of anemia
in end-stage renal disease patients. Initial studies indicated
an improvement in quality of life [1]. However, neutral/
negative data from two randomized controlled trials testing
RhEPO to correct anemia in chronic kidney disease (CKD)
were recently reported [2, 3]. The CHOIR study evaluated
the effects of achieving high Hb levels (13.5 g/dl)
compared to lower Hb levels (11.3 g/dl) on cardiovascular
complications in CKD patients with an eGFR ≤50 ml/min/
1.73 m
2. This study was prematurely halted, because of an
increased adverse event rate in the high Hb group [2]. The
CREATE study evaluated the effect of complete Hb
correction (13.0 to 15.0 g/dl) to lower hemoglobin (Hb)
correction (10.5–11.5 g/dl) in CKD patients with an eGFR
<35 ml/min/1.73 m
2. In these patients complete correction
of Hb did not change the risk on cardiovascular events [3].
So, both studies failed to demonstrate a better survival by
correcting Hb levels to normal values, although both
studies had an open-label design and were not placebo-
controlled. Currently, a large, randomized, placebo-con-
trolled, double blind trial to evaluate the effect of RhEPO
treatment (to achieve Hb levels of 13.0 g/dl) on cardiovas-
cular events in anemic CKD patients (TREAT) is ongoing
[4]. A recent statement from the DSMB conveyed no
evidence for terminating the TREAT study. Of note, this
analysis was based on more endpoints than both CREATE
and CHOIR together.
In contrast to studies in CKD patients, two recent
randomized, double-blind, placebo controlled studies with
anemic chronic heart failure (CHF) patients consistently
indicated beneficial cardiovascular and quality of life
effects of RhEPO treatment [5, 6]. The first study by
Ponikowski et al. [5] included 41 anemic CHF patients who
were randomly assigned to either receive darbepoetin-alpha
or placebo for 26 weeks to reach a target Hb of 13–15 g/dl.
RhEPO increased Hb and in the treatment group, quality of
life improved and a trend towards exercise duration was
observed. In another study, van Veldhuisen et al. [6]
evaluated the effect of weight-based and fixed starting dose
RhEPO treatment compared to placebo in 165 anemic CHF
patients. After 26 weeks, both RhEPO groups showed
similar effects on Hb concentrations and this was associated
with an improvement in quality of life. Importantly, both
studies showed no difference in the incidence of adverse
events. Thus, results from studies executed primarily in
anemic CKD patients (neutral/negative) contrasted with
results from studies executed primarily in anemic CHF
patients (mainly positive). Notably, only 32% of the
patients in CREATE and 24% in CHOIR had signs of
heart failure. Alternatively, only the minority of anemic
CHF patients had an eGFR <35–50 ml/min/1.73 m
2. So,
there was little overlap between patient groups in these
studies.
Therefore, the study by Pappas et al. [7] in this present
issue of Cardiovascular Drugs and Therapy is particularly
interesting, because it brings both worlds together. They
aimed to determine the effects of RhEPO (targeting at
Hb ≥13.0 g/dl) on cardiac structure and function in patients
with CKD. Although systolic left ventricular function was
generally normal, diastolic dysfunction and left ventricular
hypertrophy was already present in a large number of
patients. They demonstrated that RhEPO treatment resulted
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ventricular function, and a reduction in left ventricular mass
Their results support the beneficial effects of long term
RhEPO treatment on cardiac function and structure in
anemic patients with CKD and evidence of cardiac
dysfunction.
Is there an explanation for this observation? The
generally positive effects of RhEPO in CHF patients, but
not in CKD patients, suggests differential effects of RhEPO
in these two patient groups. To appreciate this, we need to
look into the mechanisms by which RhEPO exerts its
effects. We performed several experimental studies to
elucidate the working mechanism of RhEPO.
Different from the general concept, we (and others) have
shown that the beneficial cardiovascular effects of RhEPO
are not related to the increase in Hb. The effects are rather
conferred by extra-hematopoietic effects, independent from
anemia correction. In a study by Lipsic et al. [8] a low dose
of EPO did not stimulate erythropoiesis, but did have the
same positive effects on left ventricular function and
angiogenesis. Carbamylated EPO (CEPO), which lacks
erythropoietic activity, shows similar results compared to
RhEPO in the protection of myocardial tissue [9]. The
discovery of the presence of the EPO receptor (EPO-R) in
the myocardium and endothelium provided new perspec-
tives on the function of EPO besides stimulating erythro-
poiesis. First, it withholds myocardial cells from apoptosis
and thereby opposes cardiac remodeling. This anti-apoptotic
effect was found in multiple animal ischemia–reperfusion
models in which treatment with EPO resulted in a smaller
infarct size and an enhanced cardiac performance [10–12].
In addition, we recently reported that a bolus of RhEPO in
patients with an acute myocardial infarction was safe and
feasible [13], and a larger randomized, clinical efficacy trial is
currentlyongoing(ClinicalTrials.govnumber:NCT00449488).
Second, RhEPO treatment in a CHF rat model stimulates
angiogenesis and neovascularisation, which improves myocar-
dial blood flow. Our group showed that in an experimental rat
MI model, EPO treatment not only recruits endothelial
progenitor cells (EPC)s from the bone marrow, but also
demonstrated that these EPCs also home to and incorporate in
myocardial capillaries to form new vessels [14]. Because of the
experimental favorable effects on the injured myocardium,
these extra-hematopoietic effects of EPO are of great interest
in the treatment of patients with heart failure.
So, the study by Pappas et al. [7] demonstrated that
beneficial effect of RhEPO on cardiac structure and
function are also found in patients with CKD. We believe
that the cardioprotective effects of RhEPO are mainly
caused by decreasing apoptosis and by stimulating new
vessel formation and by a lesser degree through its
stimulation of erythropoiesis Whether these findings will
translate into reduction of mortality and morbidity is
currently under investigation in the RED-HF trial (Clin-
icalTrials.gov number: NCT00358215).
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